Crossmark

Ticagrelor Versus Clopidogrel as Part of Dual or Triple Antithrombotic Therapy: a Systematic Review and Meta-Analysis

Crossref DOI link: https://doi.org/10.1007/s10557-018-6795-9

Published Online: 2018-05-15

Published Print: 2018-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Andreou, Ioannis https://orcid.org/0000-0002-2912-1928
Briasoulis, Alexandros

Pappas, Christos

Ikonomidis, Ignatios

Alexopoulos, Dimitrios
License Information

Text and Data Mining valid from 2018-05-15
More Information

Article History

First Online: 15 May 2018

Compliance with Ethical Standards

:

: Dr. Alexopoulos reports advisory board fees (modest) from AstraZeneca, Boehringer Ingelheim, Bayer, and Medtronic and speaker honoraria (modest) from AstraZeneca, Bayer, and Boehringer Ingelheim. Other authors have no conflicting interests.

: This article does not contain any studies with human participants or animals performed by any of the authors.